SC refuses to bar Zydus from selling biosimilar of BMS' cancer drug
SC refuses to bar Zydus from selling biosimilar of BMS' cancer drug is drawing significant interest across the industry.
The Supreme Court has declined to halt Zydus Lifesciences from producing and selling a cancer drug biosimilar. The court emphasized public access to medicine, stating that patients should not die due to high drug costs. Bristol Myers Squibb, the patent holder, can seek compensation if infringement is proven.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Canadian government demands safety changes from OpenAI
- Trump Board of Peace still has a lot of work to do in Gaza
- INTERVIEW | Need long-term community resilience : Rohini Nilekani
- Winning it for Johnny Hockey: Team USA wins a historic gold and honors a fallen teammate
Source: Original →